

FINANCIAL TEAR SHEET

Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

Primary IR Contact

Investor Contact

Email:


IR@adaptimmune.com

Stock Performance

ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	\$10.76
Change (%)	▼ 0.12 (1.10%)
Volume	594,791
52 Week Low	\$6.60
Market Cap	\$6,163,480,832
Rolling EPS	-0.99
PE Ratio	0
Shares Outstanding	566,496,400

Data as of 10/19/18 4:00 p.m. ET



Recent Headlines & Events

10/08/18

[Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology \(ESMO\) 2018 Congress](#)

09/07/18

[Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares](#)

09/05/18

[Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares](#)

There are currently no events scheduled.

SEC Filings

FILING DATE

FORM

Corporate Governance

[James Noble](#)

Chief Executive Officer

10/10/18	<u>SC 13G/A</u>	<u>Bent Jakobsen, PhD</u>	Scientific Founder
10/10/18	<u>SC 13D/A</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Business Officer
10/02/18	<u>4</u>	<u>Rafael Amado, MD</u>	Chief Medical Officer
09/17/18	<u>SC 13D</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
		<u>Gwendolyn Binder, PhD</u>	Chief Technology Officer
		<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.